Research Summary

I am a physician scientist who works in translational cancer research and medical oncology. My clinical practice is in the Cancer Immunotherapy Clinic, where I work with patients with solid organ cancers who are being treated on early phase immunotherapy trials. I also attend on the Oncology Consult inpatient service. My research interests are in studying the mechanisms of response and resistance to immunotherapy, with a focus on gastrointestinal cancers.


  • Loyola University, BS, 2006, Biology, Chemistry
  • Johns Hopkins University, MD, PhD, 2015, Medicine, Immunology
  • University of California San Francisco, Residency, 2017, Internal Medicine
  • University of California San Francisco, Fellowship, Hematology/Oncology

Honors & Awards

  • 2022
    ImFLAME Young Investigator Award
  • 2022 
    HDFCCC K12 Physician Scholar Program in Clinical Oncology Career Development Award
  • 2022
    UCSF Liver Center Liver Center Pilot/Feasibility Grant Awardee
  • 2022
    HDFCCC Cancer Immunology and Immunotherapy Pilot Grant Awardee
  • 2021
    UCSF Chancellor Award for Advancement of Women
  • 2021
    The Cholangiocarcinoma Foundation Research Fellowship Award
  • 2020
    UCSF Exceptional Physician Award Honorable Mention
  • 2020
    ANCO (Association of Northern California Oncologists) Travel Award
  • 2020
    ASCO Conquer Cancer Foundation Young Investigator Award
  • 2020
    Society for Translational Oncology Fellows’ Forum, selected participant
  • 2019
    Scholar-in-Training Award, AACR Annual Meeting 2019
  • 2018-2019
    UCSF Fellowship Leadership Cohort 
  • 2018, 2019
    Immunology T32 training grant recipient
  • 2018
    UCSF Academy of Medical Educators Innovations Funding for Education Grant Awardee 
  • 2018
    AACR Molecular Biology in Clinical Oncology course participant 
  • 2017
    UCSF Excellence and Innovation Award in Graduate Medical Education for developing WILD (Women in Leadership Development) annual symposium

Selected Publications

  1. Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, Kudo M, Yang JD, Pinato DJ, Ji F. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2023 Aug 24.  View on PubMed
  2. Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center. Oncologist. 2023 Jul 13.  View on PubMed
  3. Gordan JD, Keenan BP, Lim HC, Yarchoan M, Kelley RK. New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma. Drugs. 2023 Aug; 83(12):1091-1109.  View on PubMed
  4. Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. J Immunother Cancer. 2023 06; 11(6).  View on PubMed
  5. Ana I. Velazquez Manana, Bismarck Odei, Narjust Florez, Sankalp Pandya, Valerie M Dandar, Dame Idossa, Bridget P. Keenan, Katherine Van Loon, Fumiko Chino. Should I stay, or should I go? Factors associated with intent to leave academic oncology. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):11004-11004.  View on PubMed
  6. Keenan BP, Barr E, Gleeson E, Greenberg CC, Temkin SM. Structural Sexism and Cancer Care: The Effects on the Patient and Oncologist. Am Soc Clin Oncol Educ Book. 2023 May; 43:e391516.  View on PubMed
  7. Hewitt Chang, Luchia Andemicael, Moshiur Mekhail Anwar, John Gordan, Jamese Johnson, Bridget P Keenan, Robin Kate Kelley, Andrew H. Ko, Katherine Van Loon, Alan P. Venook, Lawrence Fong, Melody Ju Xu, Mary Uan-Sian Feng. A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI). Journal of Clinical Oncology. 2023 Feb 1; 41(4_suppl):tps817-tps817.  View on PubMed
  8. Luchia Andemicael, Hewitt Chang, Moshiur Mekhail Anwar, Kelly Bauer, John Gordan, Jamese Johnson, Bridget P Keenan, Alan P. Venook, Chia-Ching Jackie Wang, Karen Zhang, Lawrence Fong, Robin Kate Kelley, Mary Uan-Sian Feng. Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy. Journal of Clinical Oncology. 2023 Feb 1; 41(4_suppl):tps630-tps630.  View on PubMed
  9. Maira Soto, Erin L Filbert, Hai Yang, Li Zhang, Stephanie Starzinski, Alec Starzinski, Alexander Cheung, Tony Li, Frank J. Hsu, Andrew H. Ko, Lawrence Fong, Bridget P Keenan. Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer. Journal of Clinical Oncology. 2023 Feb 1; 41(4_suppl):450-450.  View on PubMed
  10. Keenan BP, McCarthy EE, Ilano A, Yang H, Zhang L, Allaire K, Fan Z, Li T, Lee DS, Sun Y, Cheung A, Luong D, Chang H, Chen B, Marquez J, Sheldon B, Kelley RK, Ye CJ, Fong L. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell Rep. 2022 09 20; 40(12):111384.  View on PubMed
  11. A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran. 1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers. Annals of Oncology. 2022 Sep 1; 33:s1111.  View on PubMed
  12. Andrea Grace Bocobo, Renee Wang, Spencer Behr, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Lawrence Fong, Bridget P Keenan, Wesley Allen Kidder, Andrew H. Ko, Kanti Pallav Kolli, Megan Kennedy, Angela Laffan, Sorbarikor Piawah, Marin Pollak, Gabriel Schwartz, Julia Whitman, Li Zhang, Katherine Van Loon, Chloe Evelyn Atreya. Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):3565-3565.  View on PubMed
  13. Robin Kate Kelley, Paige M. Bracci, Bridget Keenan, Spencer Behr, Faaiz Ibrahim, Marin Pollak, John Gordan, Andrew H. Ko, Katherine Van Loon, Chloe Evelyn Atreya, Pelin Cinar, Alan P. Venook, Lawrence Fong. Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial. Journal of Clinical Oncology. 2022 Feb 1; 40(4_suppl):444-444.  View on PubMed
  14. Bridget Keenan, Elizabeth McCarthy, Arielle Ilano, Hai Yang, Li Zhang, Kathryn Allaire, Zenghua Fan, Tony Li, David Lee, Yang Sun, Alexander Cheung, Hewitt Chang, Brenna Sheldon, Robin Kelley, Chun Jimmie Ye, Lawrence Fong. 676 Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer. Journal for ImmunoTherapy of Cancer. 2021 Nov 10; 9(Suppl 2):a704-a704.  View on PubMed
  15. Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. Anticancer Res. 2021 Jun; 41(6):2985-2992.  View on PubMed
  16. Keenan B, Jagsi R, Van Loon K. Pragmatic Solutions to Counteract the Regressive Effects of the COVID-19 Pandemic for Women in Academic Oncology. JAMA Oncol. 2021 06 01; 7(6):825-826.  View on PubMed
  17. Keenan BP, Kelley RKK. Key challenges for drugs in clinical development for cholangiocarcinoma. Expert Opin Investig Drugs. 2021 Apr; 30(4):285-290.  View on PubMed
  18. Keenan BP, Fong L. Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas. Cancer Discov. 2021 01; 11(1):20-22.  View on PubMed
  19. Santhosh L, Harleman E, Venado A, Farrand E, E Gilbreth M, Keenan BP, Thompson VV, Shah RJ. Strategies for forming effective women's groups. Clin Teach. 2021 Apr; 18(2):126-130.  View on PubMed
  20. Bridget P. Keenan, Elizabeth E. McCarthy, Arielle Ilano, David S. Lee, Yang Sun, Brenna Sheldon, Alexander Cheung, Chun Jimmie Ye, Robin Kate Kelley, Lawrence Fong. Abstract 5512: Identification of circulating myeloid cells induced in advanced biliary cancer patients responding to anti-PD1 through combined single cell RNA sequencing and protein expression analysis. Cancer Research. 2020 Aug 15; 80(16_Supplement):5512-5512.  View on PubMed

Go to UCSF Profiles, powered by CTSI